The mass offshoring of a high-innovation sector in which the United States has been a global leader for decades has been happening with the knowledge and approval of pharmaceutical executives looking to make short-term profits. Naturally, it would have disastrous consequences for the United States. Beyond the national security concerns associated with losing biotech to a peer strategic adversary, biotech has become a valuable industry that provides patients with lifesaving drugs, scientists and lab technicians with high-quality jobs, and formerly deindustrialized cities with hubs of innovation. The loss of biotech to China is imminent, and it is essential for national leaders and policymakers to stem the flow with an industrial policy for biotech…

Read More